miR-625 reverses multidrug resistance in gastric cancer cells by directly targeting ALDH1A1

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research

Related Links:

This study suggested that the inhibition of P-gp activity is a novel mechanism of action by which GlcN could reverse MDR in EPG85-257RDB cells. PMID: 31290701 [PubMed - as supplied by publisher]
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Source Type: research
miR‑1 reverses multidrug resistance in gastric cancer cells via downregulation of sorcin through promoting the accumulation of intracellular drugs and apoptosis of cells. Int J Oncol. 2019 Jun 25;: Authors: Deng LM, Tan T, Zhang TY, Xiao XF, Gu H Abstract Gastric cancer (GC) is one of the most common cancers worldwide and results in the second greatest rate of cancer‑associated mortality globally. Multidrug resistance (MDR) often develops during the chemotherapy, resulting in the failure of treatment. To investigate the molecular mechanism of MDR, the roles of microRNA (miR)‑1 were studied ...
Source: International Journal of Oncology - Category: Cancer & Oncology Authors: Tags: Int J Oncol Source Type: research
In conclusion, the results improve our understanding on the characteristics of lncRNAs and mRNAs on regulating host immune response against C. perfringens type C infection, which will provide a reference for future research into exploring C. perfringens-related diseases in human. Introduction Clostridium perfringens (C. perfringens) is a Gram-positive anaerobic rod and ranks as the second most common bacteria that causes fulminant, fatal infectious and immune diseases (Scharff, 2012; Grass et al., 2013). These diseases are characterized by fever, pain, gas production, local edema, and severe tissue destruction, the...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Cosmeri Rizzato1, Javier Torres2, Elena Kasamatsu3, Margarita Camorlinga-Ponce2, Maria Mercedes Bravo4, Federico Canzian5 and Ikuko Kato6* 1Department of Translation Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy 2Unidad de Investigación en Enfermedades Infecciosas, Unidades Médicas de Alta Especialidad Pediatría, Instituto Mexicano del Seguro Social, Mexico City, Mexico 3Instituto de Investigaciones en Ciencias de la Salud, National University of Asunción, Asunción, Paraguay 4Grupo de Investigación en Biología del C&aacut...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
In conclusion, e-As4S4 holds great potential for an alternative therapeutics in the treatment of breast cancer, due to its unique function of correcting the aggressive microenvironment. Introduction Metastasis is the leading cause of breast cancer mortality, which has been one major challenge in clinical treatment (1). In particular, triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR) and HER2 receptors, which is one of the most aggressive types of breast cancers, marked by high rates of relapse, visceral metastases and early death (2, 3). The...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Lei Shang1,2 and Minjie Wei1* 1School of Pharmacy, China Medical University, Shenyang, China 2Shenyang Medical College, Shenyang, China The protein lysine methyltransferase SMYD2 has recently emerged as a new enzyme modulate gene transcription or signaling pathways, and involved into tumor progression. However, the role of SMYD2 in drug resistant is still not known. Here, we found that inhibition of SMYD2 by specific inhibitor could enhance the cell sensitivity to cisplatin (CDDP), but not paclitaxel, NVB, and VCR in non-small cell lung cancer (NSCLC). Further study showed that SMYD2 and its substrates were overex...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Qingbin Cui1,2, Chao-Yun Cai2, Hai-Ling Gao2,3, Liang Ren1, Ning Ji2,4, Pranav Gupta2, Yuqi Yang2, Suneet Shukla5, Suresh V. Ambudkar5, Dong-Hua Yang2 and Zhe-Sheng Chen2* 1School of Public Health, Guangzhou Medical University, Guangdong, China 2Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States 3Department of Histology and Embryology, Clinical Medical College, Weifang Medical University, Weifang, China 4Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tian...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Upregulation of DANCR can accelerate the MDR development of GC, which may become a potential target for treating GC with MDR. PMID: 31002130 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Conclusion: In Mongolia, the prevalence of H. pylori resistance is high requiring bismuth quadruple therapy or susceptibility-based therapy to obtain acceptable cure rates. Introduction As in most developing countries, the prevalence of Helicobacter pylori infection is high in Mongolia (Nyamdavaa, 2013) with reported prevalence ranging of 80% among adults (Matsuhisa et al., 2015; Khasag et al., 2018), 64% among adolescents, and 65 and 100% among pediatric patients with gastric comorbidity (Go, 2013). Gastric cancer is a common problem in Mongolia; an age-standardized rate of 33.1 per 100,000, which is the second hi...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Multidrug Resistance